A phase I study of ovarian cancer peptides plus GM-CSF and adjuvant (montanide ISA-51) as consolidation following optimal debulking and systemic chemotherapy for women with advanced stage ovarian, tubal, or peritoneal cancer

Trial Profile

A phase I study of ovarian cancer peptides plus GM-CSF and adjuvant (montanide ISA-51) as consolidation following optimal debulking and systemic chemotherapy for women with advanced stage ovarian, tubal, or peritoneal cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2012

At a glance

  • Drugs Montanide ISA-51 (Primary) ; Ovarian cancer vaccine (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Jan 2010 Planned number of patients changed from 9 to 16 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top